Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays

To the Editor The recent Research Letter comparing 2 cell-free DNA next-generation sequencing tests in prostate cancer has severe methodological flaws. It improperly confuses clinicians and implies that laboratory accreditation standards are lax. Published cell-free DNA test concordance study design criteria include:

https://ift.tt/2L9udgz